T Cell News and Research

Latest T Cell News and Research

Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure

Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure

Sonic hedgehog helps regenerate critical nerve that runs along prostate: Research

Sonic hedgehog helps regenerate critical nerve that runs along prostate: Research

ISSCR launches web site on stem cell treatments

ISSCR launches web site on stem cell treatments

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

4% of South Asian people carry mutated gene that causes heart failure

4% of South Asian people carry mutated gene that causes heart failure

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

Tel Aviv University researchers invent new tool to control risk of runaway stem cells

Tel Aviv University researchers invent new tool to control risk of runaway stem cells

Harvard and University of Montreal researchers challenge views on how cells respond to stimuli

Harvard and University of Montreal researchers challenge views on how cells respond to stimuli

Psychological intervention program teaches breast cancer patients how to cope with the disease

Psychological intervention program teaches breast cancer patients how to cope with the disease

Cellectis bioresearch, Lonza collaborate in development, commercialization of bioengineered cell line

Cellectis bioresearch, Lonza collaborate in development, commercialization of bioengineered cell line

Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO

Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NexGen Biomedical offers RNAi / PSR platform technology for sale

NexGen Biomedical offers RNAi / PSR platform technology for sale

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial

Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial

New technique to prevent tumours developing in connection with stem cell transplantations

New technique to prevent tumours developing in connection with stem cell transplantations

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

USPTO grants ISCO patent to International Stem Cell's hpSC

USPTO grants ISCO patent to International Stem Cell's hpSC

Boosting levels of ABCG1 protein in diabetics will improve insulin production

Boosting levels of ABCG1 protein in diabetics will improve insulin production

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.